Abstract: Non-coding RNA, such as miRNA, expression data derived from a cell population is used to infer the propensity of that cell population for a cellular functional effect for a pre-determined purpose, which effect is temporally, procedurally or interventionally separated from the cell population from which the expression data is derived. Thereby, the cellular functional effect of a cell population can be predicted in order to improve decisions and selections to be made relating to the use of cells, e.g. from cells deriving from different donors or batches, for use in bioprocess application or cell therapeutics, in order to enhance productivity, efficiency and/or efficacy.
Type:
Application
Filed:
February 11, 2022
Publication date:
May 26, 2022
Applicant:
SISTEMIC SCOTLAND LTD
Inventors:
David Mallinson, Donald Dunbar, Elaine Gourlay, Daria Olijnyk, James Reid
Abstract: Non-coding RNA, such as miRNA, expression data derived from a cell population is used to infer the propensity of that cell population for a cellular functional effect for a pre-determined purpose, which effect is temporally, procedurally or interventionally separated from the cell population from which the expression data is derived. Thereby, the cellular functional effect of a cell population can be predicted in order to improve decisions and selections to be made relating to the use of cells, e.g. from cells deriving from different donors or batches, for use in bioprocess application or cell therapeutics, in order to enhance productivity, efficiency and/or efficacy.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
March 8, 2022
Assignee:
SISTEMIC SCOTLAND LTD
Inventors:
David Mallinson, Donald Dunbar, Elaine Gourlay, Daria Olijnyk, James Reid
Abstract: A method for determining the presence and level of PSC contaminants in a PSC-derived cell population for use in cell therapy by assaying a sample of the PSC-derived cell population against a panel of non-coding RNAs such as miRNA known to be differentially expressed in PSC contaminants, thereby detecting residual PSC cell contamination at a level of 10 and even 5 or fewer residual contaminating PSC cells in a background of one million cells, such that a PSC-derived cell population or sample may be identified as meeting safety requirements for use in cell therapy.
Type:
Application
Filed:
January 22, 2019
Publication date:
May 13, 2021
Applicant:
SISTEMIC SCOTLAND LTD
Inventors:
David Mallinson, Elaine Gourlay, James Reid, Ditte Andersen